293 related articles for article (PubMed ID: 28281906)
1. PAD4: pathophysiology, current therapeutics and future perspective in rheumatoid arthritis.
Koushik S; Joshi N; Nagaraju S; Mahmood S; Mudeenahally K; Padmavathy R; Jegatheesan SK; Mullangi R; Rajagopal S
Expert Opin Ther Targets; 2017 Apr; 21(4):433-447. PubMed ID: 28281906
[TBL] [Abstract][Full Text] [Related]
2. Discovery of Novel Potential Reversible Peptidyl Arginine Deiminase Inhibitor.
Aliko A; Kamińska M; Falkowski K; Bielecka E; Benedyk-Machaczka M; Malicki S; Kozieł J; Wong A; Bryzek D; Kantyka T; Mydel P
Int J Mol Sci; 2019 May; 20(9):. PubMed ID: 31052493
[TBL] [Abstract][Full Text] [Related]
3. Peptidylarginine deiminase-4: Medico-formulative strategy towards management of rheumatoid arthritis.
Thirugnanasambandham I; Radhakrishnan A; Kuppusamy G; Kumar Singh S; Dua K
Biochem Pharmacol; 2022 Jun; 200():115040. PubMed ID: 35436466
[TBL] [Abstract][Full Text] [Related]
4. Protein arginine deiminase 4 (PAD4): Current understanding and future therapeutic potential.
Jones JE; Causey CP; Knuckley B; Slack-Noyes JL; Thompson PR
Curr Opin Drug Discov Devel; 2009 Sep; 12(5):616-27. PubMed ID: 19736621
[TBL] [Abstract][Full Text] [Related]
5. Peptidylarginine deiminase 2 is required for tumor necrosis factor alpha-induced citrullination and arthritis, but not neutrophil extracellular trap formation.
Bawadekar M; Shim D; Johnson CJ; Warner TF; Rebernick R; Damgaard D; Nielsen CH; Pruijn GJM; Nett JE; Shelef MA
J Autoimmun; 2017 Jun; 80():39-47. PubMed ID: 28188029
[TBL] [Abstract][Full Text] [Related]
6. Clinical and immunological aspects of anti-peptidylarginine deiminase type 4 (anti-PAD4) autoantibodies in rheumatoid arthritis.
Reyes-Castillo Z; Muñoz-Valle JF; Llamas-Covarrubias MA
Autoimmun Rev; 2018 Feb; 17(2):94-102. PubMed ID: 29196243
[TBL] [Abstract][Full Text] [Related]
7. Protein Arginine Deiminases (PADs): Biochemistry and Chemical Biology of Protein Citrullination.
Mondal S; Thompson PR
Acc Chem Res; 2019 Mar; 52(3):818-832. PubMed ID: 30844238
[TBL] [Abstract][Full Text] [Related]
8. Inhibitors and inactivators of protein arginine deiminase 4: functional and structural characterization.
Luo Y; Arita K; Bhatia M; Knuckley B; Lee YH; Stallcup MR; Sato M; Thompson PR
Biochemistry; 2006 Oct; 45(39):11727-36. PubMed ID: 17002273
[TBL] [Abstract][Full Text] [Related]
9. Discovery of a new class of inhibitors for the protein arginine deiminase type 4 (PAD4) by structure-based virtual screening.
Teo CY; Shave S; Chor AL; Salleh AB; Rahman MB; Walkinshaw MD; Tejo BA
BMC Bioinformatics; 2012; 13 Suppl 17(Suppl 17):S4. PubMed ID: 23282142
[TBL] [Abstract][Full Text] [Related]
10. Profiling Protein Arginine Deiminase 4 (PAD4): a novel screen to identify PAD4 inhibitors.
Knuckley B; Luo Y; Thompson PR
Bioorg Med Chem; 2008 Jan; 16(2):739-45. PubMed ID: 17964793
[TBL] [Abstract][Full Text] [Related]
11. Applicability of Small-Molecule Inhibitors in the Study of Peptidyl Arginine Deiminase 2 (PAD2) and PAD4.
Martín Monreal MT; Rebak AS; Massarenti L; Mondal S; Šenolt L; Ødum N; Nielsen ML; Thompson PR; Nielsen CH; Damgaard D
Front Immunol; 2021; 12():716250. PubMed ID: 34737738
[TBL] [Abstract][Full Text] [Related]
12. Autoantibodies to protein-arginine deiminase (PAD) 4 in rheumatoid arthritis: immunological and clinical significance, and potential for precision medicine.
Martinez-Prat L; Palterer B; Vitiello G; Parronchi P; Robinson WH; Mahler M
Expert Rev Clin Immunol; 2019 Oct; 15(10):1073-1087. PubMed ID: 31524005
[No Abstract] [Full Text] [Related]
13. Kinetic characterization of protein arginine deiminase 4: a transcriptional corepressor implicated in the onset and progression of rheumatoid arthritis.
Kearney PL; Bhatia M; Jones NG; Yuan L; Glascock MC; Catchings KL; Yamada M; Thompson PR
Biochemistry; 2005 Aug; 44(31):10570-82. PubMed ID: 16060666
[TBL] [Abstract][Full Text] [Related]
14. Anti-peptidylarginine deiminase-4 antibodies at mucosal sites can activate peptidylarginine deiminase-4 enzyme activity in rheumatoid arthritis.
Demoruelle MK; Wang H; Davis RL; Visser A; Hoang J; Norris JM; Holers VM; Deane KD; Darrah E
Arthritis Res Ther; 2021 Jun; 23(1):163. PubMed ID: 34092252
[TBL] [Abstract][Full Text] [Related]
15. PAD4 takes charge during neutrophil activation: Impact of PAD4 mediated NET formation on immune-mediated disease.
Liu X; Arfman T; Wichapong K; Reutelingsperger CPM; Voorberg J; Nicolaes GAF
J Thromb Haemost; 2021 Jul; 19(7):1607-1617. PubMed ID: 33773016
[TBL] [Abstract][Full Text] [Related]
16. Development and use of clickable activity based protein profiling agents for protein arginine deiminase 4.
Slack JL; Causey CP; Luo Y; Thompson PR
ACS Chem Biol; 2011 May; 6(5):466-76. PubMed ID: 21265574
[TBL] [Abstract][Full Text] [Related]
17. Proteolysis by Granzyme B Enhances Presentation of Autoantigenic Peptidylarginine Deiminase 4 Epitopes in Rheumatoid Arthritis.
Darrah E; Kim A; Zhang X; Boronina T; Cole RN; Fava A; Giles JT; Bingham III CO; Chalmers MJ; Griffin PR; Sadegh-Nasseri S; Rosen A
J Proteome Res; 2017 Jan; 16(1):355-365. PubMed ID: 27700100
[TBL] [Abstract][Full Text] [Related]
18. Peptidylarginine deiminase 4 and citrullination in health and disease.
Anzilotti C; Pratesi F; Tommasi C; Migliorini P
Autoimmun Rev; 2010 Jan; 9(3):158-60. PubMed ID: 19540364
[TBL] [Abstract][Full Text] [Related]
19. Tumor necrosis factor alpha, citrullination, and peptidylarginine deiminase 4 in lung and joint inflammation.
Bawadekar M; Gendron-Fitzpatrick A; Rebernick R; Shim D; Warner TF; Nicholas AP; Lundblad LK; Thompson PR; Shelef MA
Arthritis Res Ther; 2016 Jul; 18(1):173. PubMed ID: 27450561
[TBL] [Abstract][Full Text] [Related]
20. Screening of natural inhibitors against peptidyl arginine deiminase 4 from herbal extracts by a high-performance liquid chromatography ultraviolet-visible based method.
Zhao J; Li Y; Gao C; Zhao Z; Zhang S; Dong J; Zuo H; Chen X; Xie B; Guo Z; Wang Y; Li H; Bian Y
J Chromatogr A; 2024 Feb; 1716():464643. PubMed ID: 38232639
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
